MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584305 | Name: Bupranolol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bupranolol is an adrenergic-beta-2 antagonist that has been used for cardiac arrhythmia, angina pectoris, hypertension, glaucoma, and as an antithrombotic.

Chemical Structure

Bupranolol
Bupranolol
CAS#14556-46-8

Theoretical Analysis

MedKoo Cat#: 584305

Name: Bupranolol

CAS#: 14556-46-8

Chemical Formula: C14H22ClNO2

Exact Mass: 271.1339

Molecular Weight: 271.79

Elemental Analysis: C, 61.87; H, 8.16; Cl, 13.04; N, 5.15; O, 11.77

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Bupranolol; BRN 2272923; KL 255; Ophtorenin
IUPAC/Chemical Name
1-(tert-Butylamino)-3-((6-chloro-m-tolyl)-oxy)-2-propanol
InChi Key
HQIRNZOQPUAHHV-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H22ClNO2/c1-10-5-6-12(15)13(7-10)18-9-11(17)8-16-14(2,3)4/h5-7,11,16-17H,8-9H2,1-4H3
SMILES Code
OC(COC1=C(Cl)C=CC(C)=C1)CNC(C)(C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 271.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Martin LJ, Piltonen MH, Gauthier J, Convertino M, Acland EL, Dokholyan NV, Mogil JS, Diatchenko L, Maixner W. Differences in the Antinociceptive Effects and Binding Properties of Propranolol and Bupranolol Enantiomers. J Pain. 2015 Dec;16(12):1321-1333. doi: 10.1016/j.jpain.2015.09.004. Epub 2015 Oct 9. PubMed PMID: 26456674. 2: Weisser B, Noack E, Düsing R, Glänzer K. Assessment of beta-blocking activity of low-dose bupranolol. Int J Clin Pharmacol Res. 1989;9(1):9-14. PubMed PMID: 2565296. 3: Mishra B, Sankar C, Mishra M. Polymer based solutions of bupranolol hydrochloride for intranasal systemic delivery. J Drug Target. 2011 Apr;19(3):204-11. doi: 10.3109/1061186X.2010.492520. Epub 2010 Jun 15. PubMed PMID: 20550434. 4: Zelaszczyk D, Kozlowska H, Baranowska U, Baranowska M, Reutelsterz A, Kiec-Kononowicz K, Malinowska B, Schlicker E. Four close bupranolol analogues are antagonists at the low-affinity state of beta1-adrenoceptors. J Physiol Pharmacol. 2009 Mar;60(1):51-60. PubMed PMID: 19439807. 5: Babu RJ, Dhanasekaran M, Vaithiyalingam SR, Singh PN, Pandit JK. Cardiovascular effects of transdermally delivered bupranolol in rabbits: effect of chemical penetration enhancers. Life Sci. 2008 Jan 30;82(5-6):273-8. Epub 2007 Nov 23. PubMed PMID: 18096189. 6: Malinowska B, Kieć-Kononowicz K, Flau K, Godlewski G, Kozłowska H, Kathmann M, Schlicker E. Atypical cardiostimulant beta-adrenoceptor in the rat heart: stereoselective antagonism by bupranolol but lack of effect by some bupranolol analogues. Br J Pharmacol. 2003 Aug;139(8):1548-54. PubMed PMID: 12922943; PubMed Central PMCID: PMC1573984. 7: Chowanetz W, ter Meer P, Jany B. [Effect of bupranolol on hypoxic respiratory stimulation in healthy probands]. Klin Wochenschr. 1987 Jul 1;65(13):607-13. German. PubMed PMID: 3114548. 8: Jeck T, Edmonds D, Mengden T, Schubert M, Renz I, Weisser B, Vetter W. Betablocking drugs in essential hypertension: transdermal bupranolol compared with oral metoprolol. Int J Clin Pharmacol Res. 1992;12(3):139-48. PubMed PMID: 1473881. 9: Babu RJ, Pandit JK. Effect of cyclodextrins on the complexation and transdermal delivery of bupranolol through rat skin. Int J Pharm. 2004 Mar 1;271(1-2):155-65. PubMed PMID: 15129982. 10: Waller AR, Chasseaud LF, Bonn R, Taylor T, Darragh A, Girkin R, Down WH, Doyle E. Metabolic fate of the beta-blocker 14C-bupranolol in humans, dogs, and rhesus monkeys. Drug Metab Dispos. 1982 Jan-Feb;10(1):51-4. PubMed PMID: 6124383. 11: Babu RJ, Pandit JK. Effect of penetration enhancers on the transdermal delivery of bupranolol through rat skin. Drug Deliv. 2005 May-Jun;12(3):165-9. PubMed PMID: 16025846. 12: Kemken J, Ziegler A, Müller BW. Influence of supersaturation on the pharmacodynamic effect of bupranolol after dermal administration using microemulsions as vehicle. Pharm Res. 1992 Apr;9(4):554-8. PubMed PMID: 1495902. 13: Kemken J, Ziegler A, Müller BW. Pharmacodynamic effects of transdermal bupranolol and timolol in vivo: comparison of microemulsions and matrix patches as vehicle. Methods Find Exp Clin Pharmacol. 1991 Jun;13(5):361-5. PubMed PMID: 1921573. 14: Babu RJ, Pandit JK. Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems. Int J Pharm. 2005 Jan 20;288(2):325-34. Epub 2004 Dec 16. PubMed PMID: 15620873. 15: Leydhecker W, Krieglstein GK. The intraocular pressure responses of low-dose bupranolol (Ophtorenin) and methazolamide (Neptazane) in glaucomatous eyes. A controlled clinical study. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1979 Apr 2;210(2):135-40. PubMed PMID: 373489. 16: Wellstein A, Küppers H, Pitschner HF, Palm D. Transdermal delivery of bupranolol: pharmacodynamics and beta-adrenoceptor occupancy. Eur J Clin Pharmacol. 1986;31(4):419-22. PubMed PMID: 3028816. 17: Horinouchi T, Koike K. Functional identification of beta3-adrenoceptors in the guinea-pig ileum using the non-selective beta-adrenoceptor antagonist (+/-)-bupranolol. J Auton Pharmacol. 2000 Aug;20(4):253-8. PubMed PMID: 11260363. 18: Liu P, Li S, Jin Y, Qian L, Gao N, Yao SQ, Huang F, Xu QH, Cao Y. Red-emitting DPSB-based conjugated polymer nanoparticles with high two-photon brightness for cell membrane imaging. ACS Appl Mater Interfaces. 2015 Apr 1;7(12):6754-63. doi: 10.1021/acsami.5b00223. Epub 2015 Mar 23. PubMed PMID: 25764496. 19: Bastian B, Höh H, Ruprecht KW. Surface anesthetic effect and topical tolerance of one dose 0.25% bupranolol in eye-healthy people. Lens Eye Toxic Res. 1990;7(3-4):353-7. PubMed PMID: 2100165. 20: Krepp HP. Evaluation of the antianginal and anti-ischemic efficacy of slow-release isosorbide-5-mononitrate capsules, bupranolol and their combination, in patients with chronic stable angina pectoris. Cardiology. 1991;79 Suppl 2:14-8. PubMed PMID: 1760823.